This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 24/1/147    most recent 01.ATV.0000107030.22053.1ev1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Du, H. Articles by Grabowski, G. A. Search for Related Content PubMed PubMed Citation Articles by Du, H. Articles by Grabowski, G. A. Related Collections Animal models of human disease Genetically altered mice Lipid and lipoprotein metabolism

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:147.)
© 2004 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Reduction of Atherosclerotic Plaques by Lysosomal Acid Lipase Supplementation

Hong Du; Susan Schiavi; Nick Wan; Mark Levine; David P. Witte; Gregory A. Grabowski

From the Division and Program in Human Genetics (H.D., G.A.G.) and Division of Pathology and Laboratory Medicine (D.P.W.), Children’s Hospital Research Foundation, Cincinnati, OH, 45229; and Genzyme Corporation (S.S., N.W., M.L.), Cambridge, MA.

Correspondence to Gregory A. Grabowski, MD, Professor and Director, Division and Program in Human Genetics, 3333 Burnet Ave, Cincinnati, OH 45229-3039. E-mail greg.grabowski{at}cchmc.org

Objective— Proof of principle is presented for targeted enzyme supplementation by using lysosomal acid lipase to decrease aortic and coronary wall lipid accumulation in a mouse model of atherosclerosis.

Methods and Results— Mice with LDL receptor deficiency were placed on an atherogenic diet and developed predictable aortic and coronary atheroma. -Mannosyl-terminated human lysosomal acid lipase (phLAL) was produced in Pichia pastoris, purified, and administered intravenously to such mice with either early or late lesions. phLAL injections reduced plasma, hepatic, and splenic cholesteryl esters and triglycerides in affected mice. phLAL was detected in hepatic Kupffer cells and in atheromatous foam cells. Repeated enzyme injections were well tolerated, with no obvious adverse effects. In addition, the coronary and aortic atheromatous lesions were (1) eliminated in their early stages and (2) quantitatively and qualitatively reduced in their advanced stages.

Conclusion— These results support the potential utility of lysosomal acid lipase supplementation for the treatment of atherosclerosis, a leading cause of mortality and morbidity in Westernized nations.

Key Words: lysosomal acid lipase • atherosclerosis • lesion • mice

This article has been cited by other articles:

				D. Wu, C. Sharan, H. Yang, J. S. Goodwin, L. Zhou, G. A. Grabowski, H. Du, and Z. Guo Apolipoprotein E-deficient lipoproteins induce foam cell formation by downregulation of lysosomal hydrolases in macrophages J. Lipid Res., December 1, 2007; 48(12): 2571 - 2578. [Abstract] [Full Text] [PDF]

				B. E. Cox, E. E. Griffin, J. C. Ullery, and W. G. Jerome Effects of cellular cholesterol loading on macrophage foam cell lysosome acidification J. Lipid Res., May 1, 2007; 48(5): 1012 - 1021. [Abstract] [Full Text] [PDF]

				O. Zschenker, T. Illies, and D. Ameis Overexpression of lysosomal Acid lipase and other proteins in atherosclerosis. J. Biochem., July 1, 2006; 140(1): 23 - 38. [Abstract] [Full Text] [PDF]

				K. Tanaka, M. Sata, D. Fukuda, Y. Suematsu, N. Motomura, S. Takamoto, Y. Hirata, and R. Nagai Age-Associated Aortic Stenosis in Apolipoprotein E-Deficient Mice J. Am. Coll. Cardiol., July 5, 2005; 46(1): 134 - 141. [Abstract] [Full Text] [PDF]

				P. Dusitanond, J.W. Eikelboom, G.J. Hankey, J. Thom, G. Gilmore, K. Loh, Q. Yi, C.J.M. Klijn, P. Langton, F.M. van Bockxmeer, et al. Homocysteine-Lowering Treatment With Folic Acid, Cobalamin, and Pyridoxine Does Not Reduce Blood Markers of Inflammation, Endothelial Dysfunction, or Hypercoagulability in Patients With Previous Transient Ischemic Attack or Stroke: A Randomized Substudy of the VITATOPS Trial Stroke, January 1, 2005; 36(1): 144 - 146. [Abstract] [Full Text] [PDF]